This trial is studying a combination of drugs as a possible treatment for recurrent glioblastoma (GBM), a brain tumor.
2 Primary · 4 Secondary · Reporting Duration: 24 months
Experimental Treatment
78 Total Participants · 3 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
Massachusetts General Hospital | 100.0% |
Met criteria | 100.0% |
0 | 100.0% |